These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21304506)

  • 61. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients.
    Canet LM; Sánchez-Maldonado JM; Cáliz R; Rodríguez-Ramos A; Lupiañez CB; Canhão H; Martínez-Bueno M; Escudero A; Segura-Catena J; Sorensen SB; Hetland ML; Soto-Pino MJ; Ferrer MA; García A; Glintborg B; Filipescu I; Pérez-Pampin E; González-Utrilla A; Nevot MÁL; Conesa-Zamora P; Broeder AD; De Vita S; Jacobsen SEH; Collantes-Estevez E; Quartuccio L; Canzian F; Fonseca JE; Coenen MJH; Andersen V; Sainz J
    Pharmacogenomics J; 2019 Feb; 19(1):83-96. PubMed ID: 30287909
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis.
    Sode J; Vogel U; Bank S; Andersen PS; Hetland ML; Locht H; Heegaard NHH; Andersen V
    Pharmacogenomics J; 2018 Jan; 18(1):81-86. PubMed ID: 27698401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?
    Ongaro A; De Mattei M; Pellati A; Caruso A; Ferretti S; Masieri FF; Fotinidi M; Farina I; Trotta F; Padovan M
    Rheumatol Int; 2008 Jul; 28(9):901-8. PubMed ID: 18309487
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neutrophils of rheumatoid arthritis patients on anti-TNF-α therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels.
    Dominical VM; Bértolo MB; Almeida CB; Garrido VT; Miguel LI; Costa FF; Conran N
    Scand J Immunol; 2011 Apr; 73(4):309-18. PubMed ID: 21208248
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacogenomics: paving the path to personalized medicine.
    Patrinos GP; Innocenti F
    Pharmacogenomics; 2010 Feb; 11(2):141-6. PubMed ID: 20136354
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Personalized Medicine in Rheumatoid Arthritis].
    Kumagai S
    Rinsho Byori; 2015 Oct; 63(10):1175-81. PubMed ID: 26897853
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
    Flendrie M; Vissers WH; Creemers MC; de Jong EM; van de Kerkhof PC; van Riel PL
    Arthritis Res Ther; 2005; 7(3):R666-76. PubMed ID: 15899052
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis.
    Wu X; Sheng X; Sheng R; Lu H; Xu H
    Front Med; 2019 Aug; 13(4):411-419. PubMed ID: 30635780
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.
    Guan Y; Zhang H; Quang D; Wang Z; Parker SCJ; Pappas DA; Kremer JM; Zhu F
    Arthritis Rheumatol; 2019 Dec; 71(12):1987-1996. PubMed ID: 31342661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.
    van Baarsen LG; Wijbrandts CA; Gerlag DM; Rustenburg F; van der Pouw Kraan TC; Dijkmans BA; Tak PP; Verweij CL
    Genes Immun; 2010 Dec; 11(8):622-9. PubMed ID: 20555356
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.
    Conigliaro P; Ciccacci C; Politi C; Triggianese P; Rufini S; Kroegler B; Perricone C; Latini A; Novelli G; Borgiani P; Perricone R
    PLoS One; 2017; 12(1):e0169956. PubMed ID: 28107378
    [TBL] [Abstract][Full Text] [Related]  

  • 75. TNF inhibitors - new and old agents for rheumatoid arthritis.
    Simsek I
    Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.
    Smith SL; Plant D; Lee XH; Massey J; Hyrich K; Morgan AW; Wilson AG; Isaacs J; Barton A
    Pharmacogenomics; 2016 May; 17(7):715-20. PubMed ID: 27180831
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Personalized medicine: hype or reality.
    Chabner BA; Ellisen LW; Iafrate AJ
    Oncologist; 2013 Jun; 18(6):640-3. PubMed ID: 23814157
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Personalized medicine of type 2 diabetes.
    Jia W
    Front Med; 2013 Mar; 7(1):1-3. PubMed ID: 23292660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.